Table 3

Long-term follow-up (>24–36 months) characteristics according to genotype of FOXO3A SNP rs12212067 in patient with non-viral cardiomyopathy

Long term follow-up characteristics (>24–36 months) FOXO3A SNP rs12212067 in V- DCMi
Variable n= 88All patientsSNP carrier Mm n=16, 18.2%No SNP MM n=72 81.8%Effect sizeP value
Mean95% CIMean95% CI
Mean95% CI
Age (years)56.653.4 to 59.852.544.9 to 60.257.554.0 to 61.10.23
Δtime (months)66.258.5 to 7459.542.3 to 76.767.859.0 to 76.50.433
Echocardiographic parametersr
 LVEF (%)48.244.9 to 51.555.148.4 to 61.846.742.9 to 50.40.410.03
 ΔLVEF (%)10.97.6 to 14.217.311.3 to 23.29.45.6 to 13.20.230.033
 LVEDD (mm)54.952.6 to 57.151.848.6 to 55.055.753.0 to 58.40.339
 ΔLVEDD (mm)−4.1(−6.4) to (−1.8)−8.9(−12.3) to (−5.4)−2.8(−5.6) to (−0.1)0.250.034
 LVEDV (mL)152.8137.8 to 167.8130.5114.6 to 146.4158.6140.3 to 176.80.339
 ΔLVEDV (mL)−25.4(−41.3) to (−9.5)−58.3(−82.7) to (−34.0)−16.6(−35.2) to (−2.1)0.260.031
 LVEDVI (mL/m²)77.569.0 to 86.064.156.0 to 72.381.270.6 to 91.70.307
 ΔLVEDVI (mL/m²)−14.8(−23.8) to (−5.9)−32(−43.6) to (−20.5)−9.9(−20.7) to 0.80.260.038
 LA (mm)43.440.3 to 46.439.333.2 to 45.444.340.7 to 47.90.195
 ΔLA (mm)−2.7(−6.7) to 1.3−5.3(−11.6) to 0.9−1.9(−6.9) to 3.10.464
 IVSd (mm)10.710.2 to 11.210.99.8 to 12.010.610.0 to 11.20.698
 ΔIVSd (mm)−0.7(−1.1) to (−0.2)−0.6(−1.4) to 0.2−0.7(−1.2) to (−0.1)0.904
 LVPWs (mm)10.29.8 to 10.610.59.5 to 11.410.19.6 to 10.60.453
 ΔLVPWs (mm)−0.3(−0.7) to 0.10.2(−0.9) to 1.3−0.4(−0.9) to 0.050.242
 FS (%)27.822.4 to 33.133.37.5 to 59.126.421.0 to 31.80.293
 ΔFS (%)8.21.8 to 14.64.3(−19.8) to 28.59.11.4 to 16.80.558
Clinical parametersΦ
 Dyspnoea (%)404360.210.049
 NYHA class I (%)5916430.220.044
 NYHA class II (%)153120.804
 NYHA class III (%)141130.299
 NYHA class IV (%)120120.099
 NYHA class I–IV total (n)8316670.250.026
 Angina pectoris (%)140140.298
 CCS class 0 (%)8612740.298
 CCS class I (%)2020.712
 CCS class II (%)000
 CCS class III (%)000
 CCS class IV (%)120120.341
 CCS class 0–IV (n)516450.326
 RR sys (mm Hg)126.9121.4 o 132.5131.8117.4 to 146.2125.9119.7 to 132.10.577
 RR dia (mm Hg)73.569.9 to 77.275.767.8 to 86.673.168.9 to 77.30.546
 Pulse (n/min)75.772.0 to 79.379.973.0 to 86.774.670.4 to 78.90.128
Inflammatory markers in bloodr
 Leucocytes (cells/μL)7.46.7 to 8.17.15.5 to 8.67.56.7 to 8.30.968
 Δ Leucocytes (cells/μL))−0.4(−1.2) to 0.3−1.7(−3.0) to (−0.5)−0.1(−1.0) to 0.80.480.035
 CRP (mg/dL)2.11.2 to 3.00.20.07 to 0.32.51.4 to 3.50.440.005
 ΔCRP (mg/dL)0.3(−1.3) to 1.9−1.6(−3.8) to 0.50.6(−1.2) to 2.40.380.043
Hospitalisation rate (n)1.71.5 to 1.91.31.0 to 1.71.81.6 to 2.00.140.035
  • Data are expressed as mean with 95% CI; effect size when p≤0.05.

  • CCS, Canadian Cardiovascular Society; CRP, C-reactive protein; DCMi, dilated inflammatory cardiomyopathy; FS, fractional shortening; IVSd, intraventricular septum diameter (diastole); LA, left atrium; LVEDD, left ventricular end-diastolic diameter; LVEDV, left ventricular end-diastolic diameter volume; LVEDVI, left ventricular end-diastolic diameter volume index; LVEF, left ventricular ejection fraction; LVPWs, left ventricular posterior wall (systole); MM, major; Mm, heterozygote; NYHA, New York Heart Association; RR, blood pressure; SNP, single-nucleotide polymorphism; V- DCMi, patients with non-viral cardiomyopathy; Δ, difference between the individual values in the time interval T2 - T0.